Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
trial publishing date : 2022 - 01 - 18 save search
Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Overall Survival (OS) Versus Placebo in Certain Patients With Advanced Hepatocellular Carcinoma (HCC) Previously Treated With Sorafenib
Published: 2022-01-18 (Crawled : 01:00) - biospace.com/
MRK | $127.0 0.1% 2.37% 62K
|
Health Technology
|
| O: -0.37%
H: 0.0%
C: 0.0%
keytruda cel
ImmunityBio Announces Results of Phase 2 Metastatic Pancreatic Cancer Trial at ASCO GI With Median Overall Survival of 6.3 Months in Patients With Third-Line Disease, More Than Doubling Historical Survival
Published: 2022-01-18 (Crawled : 00:00) - biospace.com/
FNCTF | News | $11.16 1.13% -20.84% 0
|
Communications
|
| O: -0.4%
H: 0.0%
C: -0.58%
IBRX | $4.82 -12.2% -14.02% 700K
|
Manufacturing
|
| O: -1.27%
H: 0.0%
C: 0.0%
phase 2 trial disease media asco cancer pancreatic
Leap Therapeutics to Present Positive New Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab at the ASCO GI Cancers Symposium
Published: 2022-01-18 (Crawled : 00:00) - biospace.com/
LPTX | $3.29 2.81% 2.59% 0
|
Health Technology
|
| O: -4.23%
H: 0.0%
C: 0.0%
BGNE | $144.12 3.69% 3.48% 150
|
Health Technology
|
| O: -2.98%
H: 0.0%
C: 0.0%
dkn-01 symposium therapeutics asco positive cancer
STAG Industrial Announces Tax Treatment of 2021 Dividends
Published: 2022-01-18 (Crawled : 22:00) - stagindustrial.com
STAG | $34.75 -1.86% -1.84% 590
|
Finance
|
| O: 0.35%
H: 1.74%
C: -0.56%
treatment trial
Global Coalition for Adaptive Research Announces Key Updates on GBM AGILE Phase 2-3 Adaptive Platform Trial for Patients With Glioblastoma
Published: 2022-01-18 (Crawled : 22:00) - biospace.com/
BHVN | News 0 d | $38.72 -2.25% 0.78% 760K
|
Health Technology
|
| O: -1.78%
H: 0.59%
C: -1.67%
phase 2 research trial platform glioblastoma
Chimerix Announces Publication of Positive ONC201 Data from Phase 2 Study in Neuroendocrine Tumors in Clinical Cancer Research
Published: 2022-01-18 (Crawled : 22:00) - biospace.com/
CMRX | $0.906 -2.09% -2.44% 31
|
Health Technology
|
| O: -1.33%
H: 1.52%
C: -5.07%
onc201 phase 2 research positive endocrine cancer
Moleculin Announces Updated Preliminary Safety Data for Annamycin in Its Three Phase 1 Clinical Trials for Acute Myeloid Leukemia and Metastases of Soft Tissue Sarcoma
Published: 2022-01-18 (Crawled : 15:00) - biospace.com/
MBRX | $4.35 -5.44% 3.37% 7
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: 0.0%
als myeloid leukemia trials leukemia trial clinical trials phase 1 acute myeloid leukemia soft tissue
Rafael Pharmaceuticals Announces Ongoing Successful Enrollment and Opening of Additional Sites for Phase 2 Clinical Trial of CPI-613® (Devimistat) in Combination with Gemcitabine and Cisplatin in Patients with Biliary Tract Cancer
Published: 2022-01-18 (Crawled : 15:00) - biospace.com/
RFL 4 | $1.71 -4.09% 0
|
Finance
|
| O: 0.4%
H: 0.0%
C: -8.42%
cpi-613 613 phase 2 als ongoing trial gemcitabine cancer enroll
I-Mab Announces First Patient Dosed in China Phase 2 Combination Trial of Lemzoparlimab with Toripalimab in Patients with Advanced Solid Tumors
Published: 2022-01-18 (Crawled : 15:00) - biospace.com/
IMAB | $1.81 0.56% 0.28% 0
|
Health Technology
|
| O: -8.6%
H: 5.62%
C: 2.83%
phase 2 solid tumors trial china
Brazilian Health Regulatory Agency (ANVISA) Authorizes Sorrento Phase 2 Clinical Trial of COVI-MSC in COVID-19 Patients With Persistent Pulmonary Compromise After Recovery (Long-Hauler)
Published: 2022-01-18 (Crawled : 15:00) - biospace.com/
SRNE | $0.02 33.33% -8.85% 0
|
Health Technology
|
| O: 2.35%
H: 0.0%
C: 0.0%
covid-19 health phase 2 trial covid brazil
Evaxion Biotech Receives Regulatory Clearance to Initiate Phase 2 Trial of EVX-01 in Combination with KEYTRUDA® for Treatment of Melanoma
Published: 2022-01-18 (Crawled : 15:00) - biospace.com/
EVAX | $4.13 -0.24% -1.97% 0
|
Manufacturing
|
| O: 3.91%
H: 0.0%
C: -6.12%
evx-01 keytruda treatment phase 2 clearance trial biotech iot
HOOKIPA Announces First Patient Enrolled in Phase 2 Trial Evaluating HB-200 and Pembrolizumab for Treatment of Head and Neck Cancer and Reports FDA’s Fast Track Designation
Published: 2022-01-18 (Crawled : 15:00) - biospace.com/
HOOK | $0.85 11.11% 9.25% 280K
|
Health Technology
|
| O: 0.0%
H: 2.44%
C: -1.46%
hb-200 fast track designation treatment fda phase 2 fast track trial report cancer enroll designation
AffaMed Therapeutics, licensee of DEXTENZA® in Certain Asian Markets, Doses Their First Patient in Clinical Trial Evaluating the Safety and Efficacy of DEXTENZA® in China in Cataract Surgery Patients
Published: 2022-01-18 (Crawled : 13:30) - biospace.com/
OCUL | News | $4.645 -7.1% -7.64% 2.5K
|
Health Technology
|
| O: 0.99%
H: 1.3%
C: -5.54%
dextenza license trial therapeutics china
Worldwide Clinical Trials and Science 37® Partner to Advance Agile Clinical Trials™ and Accelerate Study Timelines
Published: 2022-01-18 (Crawled : 13:30) - biospace.com/
SNCE | $5.75 0.26% 49K
|
|
| O: 4.2%
H: 1.09%
C: -1.2%
als trials trial cel clinical trials
Vera Therapeutics Announces Phase 3 Clinical Trial for Atacicept in Lupus Nephritis- Positive feedback from FDA to initiate Phase 3 trial of atacicept in patients with LN -
Published: 2022-01-18 (Crawled : 13:30) - biospace.com/
VERA | $39.95 1.09% 1.05% 770K
|
Professional, Scientific, and T...
|
| O: -8.03%
H: 8.58%
C: 2.84%
fda trial therapeutics positive phase 3 lupus
Profound Medical Announces First Patients Treated in Prospective, Randomized Clinical Trial Comparing the TULSA Procedure to Radical Prostatectomy
Published: 2022-01-18 (Crawled : 13:00) - biospace.com/
PROF | News | $7.85 -5.42% -5.73% 17K
|
Health Technology
|
| O: 3.8%
H: 1.45%
C: -4.44%
ces trial
Sierra Oncology Updates Topline Data Timing for Pivotal Phase 3 Trial of Momelotinib in Myelofibrosis
Published: 2022-01-18 (Crawled : 13:00) - biospace.com/
SRRA | $54.99 0.04% 0.0%
|
Health Technology
|
| O: -4.34%
H: 0.0%
C: 0.0%
fibrosis trial topline phase 3
Alligator Bioscience Announces OPTIMIZE-1 Trial Update: Cohort Fully Dosed with No Adverse Effects Reported
Published: 2022-01-18 (Crawled : 10:00) - biospace.com/
APVO | $0.6826 -7.28% -7.84% 2.2K
|
Health Technology
|
| O: 0.14%
H: 0.0%
C: 0.0%
trial report bioscience
Ionis' partner to evaluate tominersen for Huntington's disease in new Phase 2 trial
Published: 2022-01-18 (Crawled : 07:00) - biospace.com/
IONS | $42.45 1.46% 1.45% 1.6K
|
Health Technology
|
| O: 3.23%
H: 0.0%
C: 0.0%
huntington phase 2 trial disease huntington’s disease
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Faraday Future Intelligent Electric, Inc. f/k/a Property Solutions Acquisition Corp. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - FFIE, FFIEW, PSAC, PSACW, PSACU
Published: 2022-01-18 (Crawled : 01:00) - prnewswire.com
XCUR 4 | $0.515 -4.68% -5.73% 18K
|
Commercial Services
|
| O: -0.86%
H: 0.64%
C: 0.12%
acquisition trial intel acquisition corp deadline
Gainers vs Losers
| 49% | 51% |
Top 10 Gainers
TRMK 4 | $29.89 1.81% 2.7K
|
Finance
TSHA | $2.375 1.06% 19K
|
Health Technology
TSN | $61.57 0.41% 14K
|
Consumer Non-Durables
TMUS S | $164.61 0.26% 190K
|
Communications
TTEC 4 | $8.02 1.5K
|
Commercial Services
TRMB S | $59.26 -0.42% 9.8K
|
Electronic Technology
AMED | $90.65 -0.44% 3.1K
|
Health Services
TRS 4 | $26.08 -0.76% 1K
|
Producer Manufacturing
TRV | $211.8 -0.76% 21K
|
Finance
TT | $294.15 -0.79% 21K
|
Producer Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.